Form 8-K - Current report:
SEC Accession No. 0001213900-24-103083
Filing Date
2024-11-27
Accepted
2024-11-27 09:00:25
Documents
13
Period of Report
2024-11-27
Items
Item 3.03: Material Modifications to Rights of Security Holders
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea022280301-8k_elevai.htm   iXBRL 8-K 29058
  Complete submission text file 0001213900-24-103083.txt   205088

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE elab-20241127.xsd EX-101.SCH 3021
3 XBRL LABEL FILE elab-20241127_lab.xml EX-101.LAB 34240
4 XBRL PRESENTATION FILE elab-20241127_pre.xml EX-101.PRE 22363
15 EXTRACTED XBRL INSTANCE DOCUMENT ea022280301-8k_elevai_htm.xml XML 3803
Mailing Address 120 NEWPORT CENTER DRIVE STE 250 NEWPORT BEACH CA 92660
Business Address 120 NEWPORT CENTER DRIVE STE 250 NEWPORT BEACH CA 92660 18667944940
Elevai Labs Inc. (Filer) CIK: 0001840563 (see all company filings)

EIN.: 851399981 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41875 | Film No.: 241506547
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)